mGluR5 Imaging in ALS Using PET
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05340660|
Recruitment Status : Recruiting
First Posted : April 22, 2022
Last Update Posted : April 22, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Amyotrophic Lateral Sclerosis||Radiation: [ 18 F]PSS232||Not Applicable|
With this study, the investigators want to examine whether receptors (docking points on the surface of a nerve cell) that bind an important messenger substance in the brain (glutamate) are increased in patients with amyotrophic lateral sclerosis (ALS) as the disease progresses. Based on observations from ALS models, the investigators suspect that this increase in receptors contributes to the damage to the nerve cells in ALS.
To image these receptors, the investigators use a specific radioactive substance and imaging combining positron emission tomography (PET), magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) of the brain and spinal cord.
The investigators will examine healthy people and ALS patients. The reason is that little is known about the receptor, even in healthy people. The investigators also do not know if and when the receptor is increasingly detectable in the course of the ALS disease. Only by comparing diseased and healthy people it can be determined if and when the receptor is built up in ALS patients. The investigators also hope to gain more information, e.g. about the distribution of receptors in the brain of healthy people compared to patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Metabotropic Glutamate Receptor 5 Imaging in Amyotrophic Lateral Sclerosis Using Positron Emission Tomography|
|Estimated Study Start Date :||April 2022|
|Estimated Primary Completion Date :||October 2022|
|Estimated Study Completion Date :||April 2025|
|Experimental: ALS Patient||
Radiation: [ 18 F]PSS232
[ 18 F]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients
- Change from baseline in [18F]PSS232 uptake in the brain and spinal cord in ALS patients at 6 months [ Time Frame: Baseline and 6 months ]Difference of [18F]PSS232 uptake in the brain and spinal cord of ALS patients at baseline and day 180, as assessed by PET and MRI to allow morphological mapping.
- Difference of [18F]PSS232 uptake in the brain and spinal cord between ALS patients and healthy, age and gender-matched subjects. [ Time Frame: 6 months ]Difference of [18F]PSS232 uptake in the brain and spinal cord of ALS patients and healthy subjects at baseline and day 180, as assessed by PET and MRI to allow morphological mapping
- Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of ALSFRS-R Score at day 180 [ Time Frame: 6 months ]Change from baseline to day 180 in [18F]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in the ALS Functional Rating Scale (ALSFRS-R), evaluating bulbar, respiratory, upper limb and lower limb function with a total score of 48 (minimal value 0, maximal value 48, higher scores mean a better outcome).
- Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of respiratory function, as measuerd by slow vital capacity (sVC) and sniff nasal inspiratory pressure (SNIP) at day 180 [ Time Frame: 6 months ]Change from baseline to day 180 in [18F]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in respiratory function, as measured by slow vital capacity (sVC) and sniff nasal inspiratory pressure (SNIP).
- Correlation of change from baseline of [18F]PSS232 uptake with change from baseline of ECAS at day 180 [ Time Frame: 6 months ]Change from baseline to day 180 in [18F]PSS232 uptake in the brain and spinal cord in ALS patients will be correlated to change from baseline to 180d in cognitive and behavioral function, as assessed by Edinburgh cognitive and behavioral ALS Screen (ECAS, minimal value 0, maximal value 136, higher scores mean a better outcome).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Clinically probable, probable laboratory supported, or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria (EEC) (45)
- Disease duration ≤18 months
- Pre-study ALSFRS-R progression between disease onset and screening of - 0.4 points/month or worse (calculated by ALSFRS -R total score decline form 48 divided by the months since onset of ALS symptoms)
- Upright slow vital capacity (sVC) ≥65 % of normal (best of three measurements)
Exclusion Criteria :
- Previous participation in another clinical study involving trial medication within the preceding 12 weeks
- History or presence of significant psychiatric disease, such as depression, evaluated with the ALS depression questionnaire (ADI-12) ≥ 23 (43) since depression has an impact on mGluR5 expression (44)
- Use of tobacco, including cigarettes, smokeless tobacco, cigars, and pipes; Ex- smoker having quit smoking ≥ 2 years
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05340660
|Contact: Nathalie Braun, MD, PhD||+41 71 494 35 email@example.com|
|Contact: Zylfije Dibrani||+41 71 494 35 81||Zylfije.Dibrani@kssg.ch|
|Neuromuscular Center/ALS Clinic, Cantonal Hospital St. Gallen||Recruiting|
|St. Gallen, Switzerland, 9007|
|Contact: Nathalie Braun, MD, PhD +41714943581 firstname.lastname@example.org|
|Contact: Zylifije Dibrani +41714943581 email@example.com|
|Principal Investigator: Nathalie Braun, MD, PhD|
|Principal Investigator:||Nathalie Braun, MD, PhD||Neuromuscular Center/ALS Clinic, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland|
|Responsible Party:||Nathalie Braun, Principal Investigator, Cantonal Hospital of St. Gallen|
|Other Study ID Numbers:||
BASEC Nr. 2021-01044
|First Posted:||April 22, 2022 Key Record Dates|
|Last Update Posted:||April 22, 2022|
|Last Verified:||April 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Receptor, Metabotropic Glutamate 5
Brain / diagnostic imaging
Positron-Emission Tomography / methods
Radiopharmaceuticals / pharmacokinetics*
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Spinal Cord Diseases
Central Nervous System Diseases